A5024018848- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Pancreatitis Pathology and Treatment
- COVID-19 and Mental Health
- Healthcare Decision-Making and Restraints
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Water resources management and optimization
- Inhalation and Respiratory Drug Delivery
- SARS-CoV-2 detection and testing
Mayo Clinic Health System
2021-2024
WinnMed
2021
Real-world clinical data to support the use of casirivimab-imdevimab for treatment outpatients with mild moderate coronavirus disease-19 (COVID-19) is needed. This study aimed assess outcomes COVID-19.
Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes patients who received these therapies identify factors associated with hospitalization other clinical outcomes.Adult monoclonal antibody from 19 November 2020 11 February 2021 were selected divided into those bamlanivimab (n = 2747) 849). The 28-day all-cause COVID-19-related hospitalizations between groups.The population...
The administration of spike monoclonal antibody treatment to patients with mild moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective infusion program. Rapid identification a dedicated physical infrastructure was circumvent the logistical challenges caring for infectious while maintaining compliance regulations ensuring safety our personnel other patients. Our partnerships collaborations among multiple different...
Abstract Background Breakthrough coronavirus disease 2019 (COVID-19) may occur in fully vaccinated persons. Methods We assessed the clinical outcomes of breakthrough COVID-19 individuals. Results In this cohort 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed COVID- 19, there were 107 (7.7%) required hospitalization by day 28. Hospitalization was significantly associated with number medical comorbidities. Antispike monoclonal antibody treatment a...
The clinical outcomes of patients who decline anti-spike monoclonal antibody therapies for coronavirus disease-2019 (COVID-19) is not known. Factors associated with the decision to accept or offer are established. This study aimed identify factors impacting consent and assess differences in accepted compared those declined these therapies.This retrospective cohort enrolled 2820 adult were offered therapies, bamlanivimab casirivimab-imdevimab, COVID-19 at Mayo Clinic Midwest between...
BACKGROUND. Clinical data to support the use of bamlanivimab for treatment outpatients with mild moderate coronavirus disease-19 (COVID-19) are needed.
The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study 3607 high-risk patients, was used more commonly than nirmatrelvir-ritonavir for treatment coronavirus disease 2019 (COVID-19) among older immunosuppressed and those with multiple comorbid conditions. Despite its use patients conditions, the rate progression to severe after (1.4% [95% confidence interval, 1.2%-1.7%]) significantly different from that (1.2% [.8%-1.5%]). Our...
Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. In addition, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. this context, there interest in understanding clinical benefit convalescent plasma...
Abstract Background Antispike monoclonal antibodies are recommended for early treatment of high-risk persons with mild to moderate coronavirus disease 2019 (COVID-19). However, clinical outcomes their use during the severe acute respiratory syndrome 2 Omicron wave limited. Methods This is a descriptive retrospective study adult patients who received sotrovimab (January 1–March 20, 2022) or bebtelovimab (March 21–April 30, 2022). The primary outcome was proportion progressed within 30 days...
Residents of nursing homes and long-term care facilities are at increased risk for severe coronavirus disease-19 (COVID-19) but may not be able to access monoclonal antibody therapies offered outpatient infusion centers due frailty logistical issues. We describe a mobile program patients with COVID-19 in skilled provide descriptive data on its outcomes.Retrospective cohort study.Collaboration between Mayo Clinic Southeast Minnesota was developed administer anti-spike antibodies under the FDA...
Clinical data to support the use of bamlanivimab for treatment outpatients with mild moderate coronavirus disease-19 (COVID-19) is needed.2,335 patients who received single-dose infusion between November 12, 2020 February 17, 2021 were compared a propensity-matched control 2,335 untreated COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was rate hospitalization days 14, 21 and 28.The median age population 63; 47.3% bamlanivimab-treated cohort ≥65 years; 49.3% female....
To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab treatment mild to moderate coronavirus disease 2019 (COVID-19) during severe acute respiratory 2 (SARS-CoV-2) B.1.617.2 Delta surge. This is a retrospective study high-risk patients who received for COVID-19 between August 1, 2021, December 2021. Rates disease, hospitalization, intensive care unit admission, death were assessed. Among 10,775 or surge, 287 (2.7%) developed that led...
To outline a consensus-designed process for triaging and managing patients with post-coronavirus disease (COVID-19) syndrome at Mayo Clinic.We convened central multidisciplinary team including members from the departments of general internal medicine, occupational physical medicine rehabilitation, psychology, allergy immunology, infectious disease, pulmonology, neurology, cardiology, pediatrics otorhinolaryngology membership all Clinic sites in Arizona, Florida, Iowa, Minnesota,...
Background: Real-world clinical data to support the use of casirivimab-imdevimab for treatment outpatients with mild moderate coronavirus disease-19 (COVID-19) is needed. This study aimed assess outcomes COVID-19.Methods: A retrospective cohort 696 patients who received between December 4, 2020 and April 9, 2021 was compared a propensity-matched control untreated COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, Wisconsin. Primary outcome rate hospitalization days 14, 21 28 after...
Abstract Breakthrough COVID-19 may occur in fully vaccinated persons. In this cohort of 1395 persons (mean age, 54.3 years; 60% female; median body mass index, 30.7) who developed breakthrough COVID-19, there were 107 (7.7%) required hospitalization by day 28. Hospitalization was significantly associated with the number medical comorbidities. Anti-spike monoclonal antibody treatment a lower risk (Odds Ratio: 0.227; 95% confidence interval, 0.128 - 0.403; p<0.001). The needed to treat...
To test the hypothesis that Monoclonal Antibody Screening Score performs consistently better in identifying need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during disease 2019 (COVID-19) pandemic and contemporary treatments is associated with a lower risk hospitalization.In this retrospective cohort study, we evaluated efficacy treatment compared no symptomatic adults who tested positive...
ABSTRACT Although severe coronavirus disease 2019 (COVID-19) and hospitalization associated with COVID-19 are generally preventable among healthy vaccine recipients, patients immunosuppression have poor immunogenic responses to vaccines remain at high risk of infection SARS-CoV-2 hospitalization. Additionally, monoclonal antibody therapy is limited by the emergence novel variants that serially escaped neutralization. In this context, there interest in understanding clinical benefit...